- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07869576
Cryopreserved Pre-embryo Transfer in a Cytokine-rich Medium Versus Hyaluronic Acid (CSF-EG)
Transferencia de Preembriones Criopreservados en un Medio Rico en Citoquinas Versus ácido hialurónico: Estudio clínico Aleatorizado
This multicenter, randomized, double-blind study compares a GM-CSF-enriched embryo transfer medium with a hyaluronic acid-enriched medium in women undergoing single frozen embryo transfer. It will assess whether the GM-CSF medium is non-inferior for clinical pregnancy rates. Participants will be randomly assigned to one of the two groups.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Hyaluronic acid is commonly used in embryo transfer media to support embryo-endometrial adhesion. GM-CSF is a cytokine that may help regulate cellular stress and apoptosis after embryo warming. This study will compare a GM-CSF-supplemented transfer medium with a hyaluronic acid-supplemented medium in frozen embryo transfer cycles. Its primary aim is to determine whether the GM-CSF medium is non-inferior to the hyaluronic acid medium for clinical pregnancy. The results may help inform the choice of transfer medium in assisted reproduction.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Nicolás Prados Dodd
- Telefonnummer: +34 954 28 62 74
- E-post: vida.investiga@gruporecoletas.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women aged 18 to 50 years.
- Undergoing transfer of a single cryopreserved embryo (SET) from own and/or donor gametes.
Exclusion Criteria:
- Uterine malformations or conditions that, in the physician's judgment, could affect implantation.
- Transfer of more than one embryo.
- Transfer of mosaic embryos.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: GM-CSF-supplemented transfer medium
Participants receive a single frozen embryo transfer using SAGE 1-Step medium with GM-CSF. |
Embryo transfer medium enriched with cytokines, used for the transfer of cryopreserved embryos. |
|
Aktiv komparator: Hyaluronic acid-enriched transfer medium
Participants receive a single frozen embryo transfer using EmbryoGlue medium enriched with hyaluronic acid. |
Embryo transfer medium enriched with hyaluronic acid, used for the transfer of cryopreserved embryos. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical pregnancy rate per embryo transfer
Tidsramme: 6-9 weeks of gestation after embryo transfer.
|
Proportion of embryo transfers resulting in an intrauterine gestational sac and fetal heartbeat confirmed by ultrasound. |
6-9 weeks of gestation after embryo transfer.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Biochemical pregnancy rate per embryo transfer
Tidsramme: 9-15 days after embryo transfer.
|
Proportion of participants with a positive serum β-hCG test after embryo transfer. |
9-15 days after embryo transfer.
|
|
Ongoing pregnancy rate per embryo transfer
Tidsramme: 6-9 weeks of gestation after embryo transfer.
|
Proportion of participants with embryonic heartbeat detected. |
6-9 weeks of gestation after embryo transfer.
|
|
Live birth rate per embryo transfer
Tidsramme: From embryo transfer through delivery, up to 9 months after embryo transfer.
|
Proportion of participants with a live-born infant at delivery. |
From embryo transfer through delivery, up to 9 months after embryo transfer.
|
|
Biochemical pregnancy loss rate per embryo transfer
Tidsramme: From serum β-hCG testing at 9-15 days after embryo transfer through ultrasound assessment at 6-9 weeks of gestation.
|
Pregnancy loss after a positive or indeterminate β-hCG result, without ultrasound confirmation of a gestational sac. |
From serum β-hCG testing at 9-15 days after embryo transfer through ultrasound assessment at 6-9 weeks of gestation.
|
|
Clinical pregnancy loss rate per embryo transfer
Tidsramme: After ultrasound confirmation of the gestational sac; the protocol does not specify a final follow-up time point.
|
Pregnancy loss after an intrauterine gestational sac has been confirmed. |
After ultrasound confirmation of the gestational sac; the protocol does not specify a final follow-up time point.
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2601_VAL_MA
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared with other researchers. Study results will be disseminated through publications and presentations in aggregate form.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .